97 related articles for article (PubMed ID: 571917)
1. Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
Philipp AH; Humber LG; Voith K
J Med Chem; 1979 Jul; 22(7):768-73. PubMed ID: 571917
[TBL] [Abstract][Full Text] [Related]
2. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
Humber LG; Bruderlein FT; Philipp AH; Götz M
J Med Chem; 1979 Jul; 22(7):761-7. PubMed ID: 571916
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
Humber LG; Sideridis N; Asselin AA; Bruderlein FT; Voith K
J Med Chem; 1978 Dec; 21(12):1225-31. PubMed ID: 31480
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
Voith K; Bruderlein FT; Humber LG
J Med Chem; 1978 Jul; 21(7):694-8. PubMed ID: 27637
[TBL] [Abstract][Full Text] [Related]
5. Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.
Kukla MJ; Bloss JL; Brougham LR
J Med Chem; 1979 Apr; 22(4):401-6. PubMed ID: 34721
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic activity of four analogs of butaclamol.
Collu R; Bouvier C; Basak A; Dugas H
Pharmacol Res Commun; 1985 Dec; 17(12):1153-7. PubMed ID: 2419927
[TBL] [Abstract][Full Text] [Related]
7. The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.
Chrzanowski FA; McGrogan BA; Maryanoff BE
J Med Chem; 1985 Mar; 28(3):399-400. PubMed ID: 2579238
[TBL] [Abstract][Full Text] [Related]
8. The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.
Voith K; Herr F
Psychopharmacologia; 1975 Apr; 42(1):11-20. PubMed ID: 1171496
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers.
Seeman P; Westman K; Protiva M; Jílek J; Jain PC; Saxena AK; Anand N; Humber L; Philipp A
Eur J Pharmacol; 1979 Jun; 56(3):247-51. PubMed ID: 38971
[TBL] [Abstract][Full Text] [Related]
10. Effects of chlorine substituents on the benzene rings of an analogue of the antipsychotic drug butaclamol on the interaction with dopamine and muscarinic receptors in rat brain.
Pugsley TA; Lippmann W
J Pharm Pharmacol; 1979 Jan; 31(1):47-9. PubMed ID: 32368
[No Abstract] [Full Text] [Related]
11. Conformational properties of butaclamol and isobutaclamol. Regularities in the structures of semirigid neuroleptics.
Froimowitz M; Matthysse S
Mol Pharmacol; 1983 Sep; 24(2):243-50. PubMed ID: 6193405
[TBL] [Abstract][Full Text] [Related]
12. [3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides.
Lin CW; Maayani S; Wilk S
Biochem Pharmacol; 1981 Jun; 30(11):1305-14. PubMed ID: 6168265
[No Abstract] [Full Text] [Related]
13. Behavioral studies on the enantiomers of butaclamol demonstrating absolute optical specificity for neuroleptic activity.
Voith K; Cummings JR
Can J Physiol Pharmacol; 1976 Aug; 54(4):551-60. PubMed ID: 10059
[TBL] [Abstract][Full Text] [Related]
14. Buspirone: chemical profile of a new class of anxioselective agents.
Temple DL; Yevich JP; New JS
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):4-10. PubMed ID: 6185470
[TBL] [Abstract][Full Text] [Related]
15. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain.
Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB
Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines.
Sarges R; Howard HR; Donahue KM; Welch WM; Dominy BW; Weissman A; Koe BK; Bordner J
J Med Chem; 1986 Jan; 29(1):8-19. PubMed ID: 3941416
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds.
Bruderlein FT; Humber LG
J Med Chem; 1975 Feb; 18(2):185-8. PubMed ID: 1168258
[TBL] [Abstract][Full Text] [Related]
18. [Effect of butaclamol enantiomers on hypothalamic tyrosine hydroxylase in the rat brain].
Mineeva MF; Raevskiĭ KS
Biull Eksp Biol Med; 1984 Oct; 98(10):453-6. PubMed ID: 6208950
[TBL] [Abstract][Full Text] [Related]
19. Pulsatile growth hormone and prolactin: effects of (+) butaclamol, a dopamine receptor blocking agent.
Willoughby JO; Brazeau P; Martin JB
Endocrinology; 1977 Oct; 101(4):1298-303. PubMed ID: 908278
[TBL] [Abstract][Full Text] [Related]
20. Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.
Arnt J; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
Eur J Pharmacol; 1982 Dec; 86(2):185-98. PubMed ID: 6130958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
